Tolvaptan for the treatment of liver cirrhosis oedema

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 5, 2014, Pages 461-470

  Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Albumin; Ascites; Bothersome symptom; Cirrhotic patient; Hyponatraemia; Sodium; Tolvaptan

Indexed keywords

ALBUMIN; CYTOCHROME P450 3A4; FUROSEMIDE; PLACEBO; SODIUM; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ANTIDIURESIS; AREA UNDER THE CURVE; ARTICLE; ASCITES; BODY WEIGHT; BRAIN DISEASE; CONSTIPATION; DEHYDRATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS VARICES; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; JAPAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 2 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYDIPSIA; PORTAL VEIN THROMBOSIS; POTASSIUM URINE LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE VOLUME; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANIMAL; COMPLICATION; EDEMA; TREATMENT OUTCOME;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; ASCITES; BENZAZEPINES; EDEMA; HUMANS; LIVER CIRRHOSIS; TREATMENT OUTCOME;

EID: 84903207850     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.903797     Document Type: Article

References (40)

1. D'Amico G, GarciaYTsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006;44(1):217Y31
2. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4(11):1385Y94
3. Ginès P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology 2008;48(3): 1002Y10
4. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liverYtransplant waiting list. N Engl J Med 2008;359(10):1018Y26
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11): 693Y9
6. Gao F, Gao R, Li G, et al. HealthYrelated quality of life and survival in Chinese patients with chronic liver disease. Health Qual Life Outcomes 2013;11(1):131
7. Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs 2004;5(9):977Y83
8. Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 2008;48(1):204Y13
9. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2Yreceptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099Y112
10. Sawyer WH, Pang PK, Seto J, et al. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 1981; 212(4490):49Y51
11. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPCY31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105(4): 787Y91
12. Yamamura Y, Nakamura S, Itoh S, et al. OPCY41061, a highly potent human vasopressin V2Yreceptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287(3):860Y7
13. Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, doubleYblind, placeboYcontrolled study (QUEST study). Cardiovasc Drugs Ther 2011;25(suppl 1): S33Y45
14. Okita K, Sakaida I, Okada M, et al. A multicenter, openYlabel, doseYranging study to exploratively evaluate the efficacy, safety, and doseYresponse of tolvaptan in patients with decompensated hepatic cirrhosis. J Gastroenterol 2010;45(9):979Y87
15. Sakaida I, Yanase M, Kobayashi Y, et al. ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: A multicentre, doubleYblind, parallelYgroup, phase III study. J Int Med Res 2012;40(6):2381Y93
16. Sakaida I, Yamashita S, Kobayashi T, et al. ASCITES 14YDay Administration Study Group. Efficacy and safety of a 14Yday administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res 2013;41(3):835Y47
17. Okita K, Kawazoe S, Hasebe C, et al. ASCITES DoseYFinding Trial Group. DoseYfinding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, doubleYblind, placeboYcontrolled trial. Hepatol Res 2014; 44(1):83Y91
18. Sakaida I, Kawazoe S, Kajimura K, et al. ASCITESYDOUBLEBLIND Study Group. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, doubleYblind, placeboYcontrolled trial. Hepatol Res 2014;44(1):73Y82
19. Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56(3):571Y8
20. Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a nonYpeptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 2012;73(4): 579Y87
21. Furukawa M, Umehara K, Kashiyama E. Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist. Tolvaptan Cardiovasc Drugs Ther 2011; 25(suppl 1):S83Y9
22. Shoaf SE, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther 2012;50(2):150Y6
23. Kim SR, Hasunuma T, Sato O, et al. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2Yreceptor antagonist: Results of singleY and multipleYdose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther 2011;25(suppl 1): S5YS17
24. Shoaf SE, Wang Z, Bricmont P, et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending singleYdose studies in healthy subjects. J Clin Pharmacol 2007;7(12):1498Y507
25. Oriuchi N, Nakajima T, Mochiki E, et al. A new, accurate and conventional fiveYpoint method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol 2005;35(7): 386Y90
26. Sakaida I, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in shortYterm diuretic therapy. Hepatol Res 2014;44(1):73Y82
27. EASL clinical practice guidelines on the management of ascites. spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver. J Hepatol 2010; 53(3):397Y417
28. Gine's P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology 1998;28(3):851Y64
29. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11(3):336Y43
30. Heuman DM, AbouYAssi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40(4):802Y10
31. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41(1):32Y9
32. Biggins SW, Kim WR, Terrault NA, et al. EvidenceYbased incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130(6):1652Y60
33. Wong F. Drug insight: The role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4(1):43Y51
34. Cárdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 2003;17(4):607Y22
35. Gentilini P, CasiniYRaggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial. J Hepatol 1999;30(4):639Y45
36. Romanelli RG, La Villa G, Barletta G, et al. LongYterm albumin infusion improves survival in patients with cirrhosis and ascites: An unblinded randomized trial. World J Gastroenterol 2006;12(9):1403Y7
37. Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32(2):198Y203
38. Evans TW. Review article: Albumin as a drugYbiological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16(suppl 5):6Y11
39. Péron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: A prospective pilot study. Am J Gastroenterol 2005; 100(12):2702Y7
40. Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53(2):283Y90.